University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Modafinil-Alcohol Interactions in Healthy Volunteers

Not Applicable

Terminated

Conditions: Alcohol

First Posted Date: 2006-03-21

Last Posted Date: 2011-03-25

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 32

Registration Number: NCT00305292

Locations: 🇺🇸
UCSF, San Francisco, California, United States

Evolution of Pain From Herpes Zoster

Completed

Conditions: Post-Herpetic Neuralgia
Acute Herpes Zoster

First Posted Date: 2006-03-21

Last Posted Date: 2023-05-24

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 100

Registration Number: NCT00305357

Locations: 🇺🇸
UCSF, San Francisco, California, United States

Brain Development Research Program

Recruiting

Conditions: Brain Disorders
Aicardi Syndrome

First Posted Date: 2006-03-21

Last Posted Date: 2023-10-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 2000

Registration Number: NCT00305305

Locations: 🇺🇸
University of California, San francisco, San Francisco, California, United States

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: irinotecan hydrochloride

First Posted Date: 2006-03-17

Last Posted Date: 2018-01-17

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 9

Registration Number: NCT00303992

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: sargramostim
Drug: busulfan
Drug: etoposide
Drug: fludarabine phosphate
Drug: prednisone
Drug: tacrolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-17

Last Posted Date: 2013-08-14

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 5

Registration Number: NCT00304018

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 2

Withdrawn

Conditions: Anemia
Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2006-03-13

Last Posted Date: 2012-10-02

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00301912

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Phase 2

Completed

Conditions: Congenital Amegakaryocytic Thrombocytopenia
Severe Congenital Neutropenia
Diamond-blackfan Anemia
Leukemia
Myelodysplastic Syndromes

Interventions: Biological: alemtuzumab
Drug: busulfan
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: methotrexate
Drug: methylprednisolone
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-13

Last Posted Date: 2017-09-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 35

Registration Number: NCT00301834

Locations: 🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Leukemia
Lymphoma
Myelodysplastic Syndromes

Interventions: Biological: anti-thymocyte globulin
Biological: sargramostim
Drug: busulfan
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Drug: tacrolimus
Procedure: umbilical cord blood transplantation

First Posted Date: 2006-03-13

Last Posted Date: 2017-10-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 7

Registration Number: NCT00301951

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Not Applicable

Terminated

Conditions: Lymphoma
Leukemia

First Posted Date: 2006-03-13

Last Posted Date: 2013-07-15

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 8

Registration Number: NCT00301860

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Radiation Therapy in Treating Women With Invasive Breast Cancer

Early Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2006-03-10

Last Posted Date: 2013-08-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 20

Registration Number: NCT00301041

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy